What is the future for hepatitis treatments? And how we can fund hepatitis programmes?

28 Feb 2015 Bridie Taylor

Discussions around hepatitis are dominated by the pioneering new treatments rapidly transforming the landscape and the ensuing heated discussions over the cost of a cure. But with such noise on the topic and few viable solutions presented, the World Hepatitis Alliance was compelled to address this gap and hosted the first World Hepatitis Advisory Committee Meeting (WHAC): a three day meeting held from 11th-13th February that focused on two key questions: What is the future for hepatitis treatment? And how can we find ways to fund hepatitis programmes? 

To best prepare for possible ways to finance hepatitis treatments and tackle the disease, we feel it is crucial to have a comprehensive understanding of upcoming drugs. To gain an insight into the new treatments on the horizon, the first half of the WHAC Meeting focused on pharmaceutical companies’ pipeline of new drugs and the access programmes they plan to roll out. The second half of the WHAC meeting then featured presentations from experts in healthcare financing from all over the world: Rita Perakis from the Center for Global Development and Diana Mak from Social Finance spoke about development impact bonds; Andreas Seiter from the World Bank presented on AIM 2030, an initiative to maximise access to medicine for priority diseases in low- and middle income countries; Thierry van Bastelaer from the Microinsurance Network delivered a presentation on the use of microinsurance for healthcare; Cristian Mazilu from Banat Consultanta explained the experience his firm in Romania has had in providing individual loans to fund hepatitis C treatment and Onno Schellekens from PharmAccess discussed his organisation’s experiences in financing mechanisms for HIV in Africa.   

Expand your knowledge of healthcare financing and join us on the quest to find pioneering new ways to address the access to hepatitis treatment by reading the WHAC report here.